Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-5421 in Multiple Myeloma
NCT07652281Phase 1Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Jul 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-5421 in multiple myeloma (MM), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoint: Recommended Phase II Dose at 24 months. Started Jul 2026; status: recruiting.
02
Drugs
SHR-5421
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07652281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07652281.